Skip to main content
Publications
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Strober B, Zhao Y, Herrera V, Wolin D, McLeod L, Eid D, Bello T. Secukinumab provides greater symptom control in psoriasis-related pain, itching, and scaling compared with previous treatments: evidence from a real-world study in the US. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.